echemi logo
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > BMS's PD-1 mono-antiOpdivo, FDA approved for late esophageal squamous cell carcinoma

    BMS's PD-1 mono-antiOpdivo, FDA approved for late esophageal squamous cell carcinoma

    • Last Update: 2020-06-16
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit
    Bristol Myers Squibb incannounced that the FDA has approved its PD-1 monoanti-Opivo (nivolumab) for patients with progressive, recurrent or metastatic esophagus squamous cell carcinoma (ESCC) who were previously unable to remove diseases after fluororide and platinum chemotherapyThe company noted that Opdivo is the first immunotherapy to treat the disease regardless of the level of tumor PD-L1 expressionThe approval was based on the results of the phase III ATTRACTION-3 trial, in which Opdivo's overall survival (OS) was superior to sequoia chemotherapyThe results showed that Opdivo had a median OS of 10.9 months, while the median OS for Dosi eyew or yew alcohol was 8.4 monthsLast July, the FDA approved Merck's PD-1 monoanti-Keytruda (pembrolizumab) for the treatment of recurrent esophagus localized late or metastatic squamous cell carcinoma, but required patients to have a tumor expression PD-L1 with a comprehensive positive score (CPS) of at least 10, and to develop disease progression after previous treatments in one or more of the body
    This article is an English version of an article which is originally in the Chinese language on and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to with relevant evidence.